as 11-21-2024 4:00pm EST
Stocks
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Founded: | 2021 | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 91.0M | IPO Year: | 2024 |
Target Price: | $13.33 | AVG Volume (30 days): | 202.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.57 | EPS Growth: | N/A |
52 Week Low/High: | $1.08 - $46.00 | Next Earning Date: | 11-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
FBLG Breaking Stock News: Dive into FBLG Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
8 hours ago
MT Newswires
2 days ago
GlobeNewswire
2 days ago
GlobeNewswire
7 days ago
Simply Wall St.
7 days ago
GlobeNewswire
9 days ago
GlobeNewswire
23 days ago
GlobeNewswire
24 days ago
The information presented on this page, "FBLG FIBROBIOLOGICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.